Related Experiment Video
Updated: Apr 20, 2026
Simultaneous PET/MRI Imaging During Mouse Cerebral Hypoxia-ischemia
Published on: September 20, 2015
Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved
Seymur Gahramanov1, Csanad Varallyay, Rose Marie Tyson
1Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Aims:
This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.
Methods:
A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.
Results:
Median survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p < 0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.
Conclusion:
Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.
Insights
Glioblastoma patients experiencing pseudoprogression, especially with MGMT promoter methylation, showed significantly better survival rates. Differentiating pseudoprogression from tumor progression using perfusion MRI is crucial for accurate prognosis.
Area of Science:
- Neuro-oncology
- Radiology
- Oncology
Background:
- Glioblastoma is an aggressive brain tumor with a poor prognosis.
- Distinguishing pseudoprogression from true tumor progression is critical for treatment planning and patient management.
- Pseudoprogression can mimic tumor progression on standard imaging, leading to potential overtreatment.
Purpose of the Study:
- To determine the survival outcomes of glioblastoma patients with and without pseudoprogression.
- To investigate the role of MGMT promoter methylation in patients with pseudoprogression.
- To highlight the importance of advanced imaging techniques in differentiating pseudoprogression.
Main Methods:
- Retrospective analysis of 68 glioblastoma patients.
- Comparison of overall survival between patients with and without pseudoprogression.
- Diagnosis of pseudoprogression primarily utilized perfusion MRI with ferumoxytol.
- Analysis of MGMT methylation status in pseudoprogression cases.
Main Results:
- Patients with pseudoprogression (35.3%) had significantly longer median survival (34.7 months) compared to those without (13.4 months) (p < 0.0001).
- The longest median survival (54.1 months) was observed in patients with both pseudoprogression and MGMT promoter methylation.
- Patients without pseudoprogression exhibited poor survival outcomes.
Conclusions:
- Pseudoprogression is a favorable prognostic indicator in glioblastoma, particularly when associated with MGMT promoter methylation.
- Accurate differentiation between tumor progression and pseudoprogression using perfusion MRI is essential for optimizing patient care.
- Identifying pseudoprogression can prevent unnecessary aggressive treatments and improve patient outcomes.
